Warning letter
Jiangsu Hengrui Pharmaceuticals Co., Ltd.: warning letter of Jul 11, 2024
FDA warning letter 679790 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 679790 |
|---|---|
| Company | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Jul 11, 2024 |
| Posted date | Jul 16, 2024 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 211.22, 211.42(c)(10) |
| Inspection city | Lianyungang |
| Inspection start date | Jan 8, 2024 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: